Sept. 17, 2020 |
|
Dec. 08, 2020 |
|
jRCTs031200124 |
Study on the use of Convalescent plasma therapy as a COVID-19 treatment (Study on the use of Convalescent plasma therapy as a COVID-19 treatment) |
|
COVIPLA-R (COVIPLA-R) |
Kutsuna Satoshi |
||
National Center for Global Health and Medicine |
||
1-21-1, Toyama, Shinjuku-ku, Tokyo |
||
+81-3-3202-7181 |
||
skutsuna@hosp.ncgm.go.jp |
||
Saito Sho |
||
National Center for Global Health and Medicine, Disease control and prevention center |
||
1-21-1, Toyama, Shinjuku-ku, Tokyo |
||
+81-3-3202-7181 |
||
ssaito@hosp.ncgm.go.jp |
Oct. 01, 2020 |
||
59 | ||
Interventional |
||
single arm study |
||
open(masking not used) |
||
historical control |
||
single assignment |
||
treatment purpose |
||
none |
||
1) Written consent obtained from the patient or his/her legal representative. |
||
1) Pregnant or breastfeeding at enrollment |
||
20age old over | ||
No limit | ||
Both |
||
COVID-19, Coronavirus disease |
||
C000705128 |
||
COVID-19 convalescent plasma therapy, Immunoglobulin therapy |
||
Administration of COVID-19 convalescent plasma 200 mL collected from patients recovered from COVID-19 |
||
C000657245 |
||
COVID-19, coronavirus disease, SARS-CoV-2, 2019-nCoV |
||
Use of ventilator or death at 14 days post-administration |
||
SARS-CoV-2 virus copy tested in nasopharynx swab at 14 days post administration, clinical recovery at 14 days post administration, chronological change in blood test results, adverse reaction occurence after administration |
Recruiting |
Ministry of Health, Labour, and Welfare; In house fund; and Japan Agency for Medical Research and Development | |
Not applicable |
Institutional Review Board for Clinical Research of National Center for Global Health and Medicine | |
1-21-1 Toyama, Shinjuku-ku, Tokyo, Tokyo | |
+81-3-3202-7181 |
|
rinrijm@hosp.ncgm.go.jp | |
Approval | |
Sept. 15, 2020 |